On Sept. 16, 2021, Novavax announced its participation in a newly expanded Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 3 (Com-COV3), led by the University of Oxford and funded by the UK Vaccines Taskforce and the National Institute for Health Research.

Novavax’s recombinant nanoparticle COVID-19 vaccine candidate, NVX-CoV2373, was one of the three COVID-19 vaccines that were to be studied in adolescents to evaluate the potential for combined regimens that mix vaccines from different manufacturers to achieve immune protection against COVID-19.